Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

Fig. 2

Flowcharts summarizing the 3 + 3 dose escalating study design. In the first cohort of patients evofosfamide will be administered at a dose of 120 mg/m2. Depending on the observed toxicity, we will escalate to dose level 2, or de-escalate to dose level -1. In further dose levels we can only escalate to the next dose (up to 340 mg/m2) or stop due to dose limiting toxicity

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us